Anzeige
+++In 69 Tagen gilt das Pentagon-China-Magnetverbot.: Dieser Tiefsee-Explorer reichte sein Wehrtechnik-Angebot ein+++
PortfolioPlus
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
FIBROGEN Forum: Community User: NOK
Kommentare 212
Summer.76,
08.08.2023 6:03 Uhr
0
FibroGen Reports Second Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/08/07/2720096/33525/en/FibroGen-Reports-Second-Quarter-2023-Financial-Results.html
Summer.76,
26.06.2023 14:13 Uhr
0
FibroGen's drug fails late-stage trial for treating lung disease
https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-lung-disease-treatment-fails-late-stage-trial-2023-06-26/
Summer.76,
26.06.2023 14:13 Uhr
0
https://www.globenewswire.com/news-release/2023/06/26/2694309/0/en/FibroGen-Announces-Topline-Results-from-Phase-3-ZEPHYRUS-1-Study-of-Pamrevlumab-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html
Summer.76,
07.06.2023 14:42 Uhr
0
https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-neuromuscular-disorder-drug-fails-late-stage-study-2023-06-07/
FibroGen's neuromuscular disorder drug fails in late-stage study
Summer.76,
18.05.2023 16:39 Uhr
0
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-topline-results-china-pivotal-phase
• Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa
• Plan to file supplemental New Drug Application in China
Summer.76,
09.05.2023 6:12 Uhr
0
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
https://www.globenewswire.com/news-release/2023/05/08/2663795/33525/en/FibroGen-Enters-into-Exclusive-License-for-FOR46-with-Fortis-Therapeutics.html
Summer.76,
09.05.2023 6:12 Uhr
0
FibroGen Reports First Quarter 2023 Financial Results
https://finance.yahoo.com/news/fibrogen-reports-first-quarter-2023-200100063.html
Summer.76,
01.05.2023 13:59 Uhr
0
https://beststocks.com/fibrogen-secures-nondilutive-term-loan-financ/
Summer.76,
27.02.2023 22:21 Uhr
0
https://seekingalpha.com/news/3941377-fibrogen-gaap-eps-of-0_70-beats-0_25-revenue-of-34_37m-beats-10_42m
FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M
Summer.76,
27.02.2023 22:14 Uhr
0
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
https://www.globenewswire.com/news-release/2023/02/27/2616460/33525/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html
• Topline Data from Five Pivotal Phase 3 Trials in 2023
• Total Company Revenue $140.7 Million in 2022
• Continued Strong Roxadustat Volume Growth in China
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Trading- und Aktien-Chat | ||
| 2 | VONOVIA Hauptdiskussion | +0,20 % | |
| 3 | Security der nächsten Generation | -8,62 % | |
| 4 | Aktuelles zu Almonty Industries | +1,49 % | |
| 5 | für alle, die es ehrlich meinen beim Traden. | ||
| 6 | ROLLS ROYCE Hauptdiskussion | -10,29 % | |
| 7 | Ecograf - ein Stern am Graphithimmel | -3,45 % | |
| 8 | XRP zu USD Hauptdiskussion | -0,56 % | |
| 9 | Quantum Emotion, redefrei | -8,62 % | |
| 10 | PLUG POWER Hauptdiskussion | -1,44 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | VONOVIA Hauptdiskussion | +0,20 % | |
| 2 | Security der nächsten Generation | -7,33 % | |
| 3 | Aktuelles zu Almonty Industries | +1,20 % | |
| 4 | ROLLS ROYCE Hauptdiskussion | -10,29 % | |
| 5 | Ecograf - ein Stern am Graphithimmel | -3,45 % | |
| 6 | BioNTech Hauptdiskussion | -1,73 % | |
| 7 | Quantum Emotion, redefrei | -7,33 % | |
| 8 | DRONESHIELD LTD Hauptdiskussion | -2,91 % | |
| 9 | PLUG POWER Hauptdiskussion | ±0,00 % | |
| 10 | BAYER Hauptdiskussion | -0,25 % | Alle Diskussionen |